Patents by Inventor Olivia Jennifer Razo

Olivia Jennifer Razo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20240084010
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 14, 2024
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Bryan Allen IRVING, Sherry Lynn LA PORTE, Jason Gary SAGERT, Daniel Robert HOSTETTER, Olivia Jennifer RAZO, Clayton William WHITE, Jennifer Hope RICHARDSON
  • Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
    Patent number: 11802158
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: October 31, 2023
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20210047406
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: April 24, 2020
    Publication date: February 18, 2021
    Inventors: Bryan Allen IRVING, Sherry Lynn LA PORTE, Jason Gary SAGERT, Daniel Robert HOSTETTER, Olivia Jennifer RAZO, Clayton William WHITE, Jennifer Hope RICHARDSON
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20200308290
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 1, 2020
    Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
    Patent number: 10669337
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 2, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • FC VARIANTS
    Publication number: 20180251565
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.
    Type: Application
    Filed: February 22, 2018
    Publication date: September 6, 2018
    Inventors: Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20170233481
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • ANTI-CD3 ANTIBODIES, ACTIVATABLE ANTI-CD3 ANTIBODIES, MULTISPECIFIC ANTI-CD3 ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20160194399
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 7, 2016
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • Methods for identifying antibodies with reduced immunogenicity
    Patent number: 9279016
    Abstract: The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-? antibody having reduced immunogenicity as compared to the reference anti-TNF-? reference antibody.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: March 8, 2016
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Olivia Jennifer Razo
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20150010539
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 8, 2015
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
  • FC VARIANTS
    Publication number: 20140377253
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 25, 2014
    Applicant: ABBVIE BIOTHERAPEUTICS INC.
    Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
  • METHODS FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY
    Publication number: 20140227251
    Abstract: The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-? antibody having reduced immunogenicity as compared to the reference anti-TNF-? reference antibody.
    Type: Application
    Filed: September 18, 2013
    Publication date: August 14, 2014
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. HARDING, Olivia Jennifer Razo